Richard Cain
Family · Livingston, TXNPI 1700236510
Payments from drug & device makers
Across 392 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$956
- Bayer$736
- Novo Nordisk$688
- AstraZeneca$504
- AbbVie$423
- Mylan Specialty L.p.$357
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,844100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 56 | $956 |
| Bayer | 40 | $736 |
| Novo Nordisk | 39 | $688 |
| AstraZeneca | 29 | $504 |
| AbbVie | 21 | $423 |
| Mylan Specialty L.p. | 15 | $357 |
| Novartis | 16 | $326 |
| Lilly USA, LLC | 19 | $299 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $289 |
| Merck | 16 | $261 |
| Paratek Pharmaceuticals, Inc. | 20 | $250 |
| Sumitomo Pharma America, Inc. | 12 | $231 |
| Amgen | 11 | $176 |
| Johnson & Johnson | 9 | $146 |
| Pfizer | 8 | $143 |
| Abbott | 8 | $131 |
| Sunovion Pharmaceuticals Inc. | 8 | $120 |
| Dexcom, Inc. | 6 | $110 |
| Exact Sciences | 6 | $97 |
| Boehringer Ingelheim | 6 | $95 |
| Viatris Specialty LLC | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 4 | $65 |
| Inspire Medical Systems, Inc. | 2 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $47 |
| Astellas Pharma US Inc | 3 | $39 |
| Calliditas Therapeutics US Inc. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Radius Health, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
How this compares
$6,844 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $100,181 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 131 | $99,213 |
| MounjaroTirzepatide | 52 | $64,891 |
| EliquisApixaban | 60 | $55,702 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 44 | $45,908 |
| XareltoRivaroxaban | 30 | $37,095 |
| GemtesaVibegron | 59 | $35,078 |
| RexultiBrexpiprazole | 30 | $33,259 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $28,841 |
| MyrbetriqMirabegron | 29 | $24,173 |
| GlyxambiEmpagliflozin/Linagliptin | 32 | $23,677 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 18 | $22,030 |
| JardianceEmpagliflozin | 22 | $20,548 |
| FarxigaDapagliflozin Propanediol | 27 | $19,696 |
| LinzessLinaclotide | 31 | $18,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Tresiba | $688 | $125,96194 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $956 | $116,687160 claims |
| Boehringer IngelheimGlyxambi, Jardiance, Synjardy Xr, Combivent Respimat | $95 | $73,58789 claims |
| Lilly USA, LLCMounjaro | $299 | $64,89152 claims |
| PfizerEliquis, Premarin | $143 | $59,96375 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $13 | $45,90844 claims |
| Johnson & JohnsonXarelto | $146 | $37,09530 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $231 | $35,07859 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $65 | $33,25930 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $504 | $29,84241 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $24,17329 claims |
| AbbVieLinzess | $423 | $18,41831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Livingston
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.